The Occam's Razor theory of BIEL's success. So what is this

New Post Public Reply Private Reply Replies (4) Message Board
WBeacham Zattnt #6346
409
The Occam's Razor theory of BIEL's success. So what is this Occam's Razor and can I put it on my lunch salad? Namesake William of Occam said the best explanation of any phenomenon is the one that makes the fewest assumptions. Remember, however, that Occam’s razor is a heuristic, a rule of thumb, to suggest which hypothesis is most likely to be true ... It doesn’t prove or disprove, it simply leads you down the path that’s most likely to be correct. https://conceptually.org/concepts/occams-razor And no, you can't put it on your salad, lunch or otherwise.

I bring up O.R. in reference to multiple allegations against BIEL and their potential success. Also affords me the opportunity to ridicule the bashturds; always a good time. Here's the list of hot-button issues for BIEL: Manufacturing, Customer Base (actual & potential), Distributors, Agreements & Contracts; NDAs, New Product Designs, International Approvals & Clearances (ref: Synergy), etc. In other words, Bashturds hate all things BIEL.

Manufacturing - I know you need all the other stuff but w/o product to sell and distribute, you got nothin'. All the other categories are rendered moot. Currently, we can only verify that product is (in the least, was) coming from China.

There's lots of turmoil regarding China and most of it is misinformed, oftentimes w/ malicious intent for nefarious reasons. I can expound on the topic at length but I won't. The long and short of it is shipping from China is unreliable (long distance) w/ long wait times (voyage, customs, etc.) and recently intermittent b/c of << fill in the blank >>. Also, communications could get awkward due to the language barrier and time differences. Time sensitive requests or special orders would really be a problem. BIEL CEO Kelly has stated that 'chip availability' for our devices won't be a problem for the future; a year she said? I, and many others, believe her and many don't. Whether you do or not, we need a chip supplier and fabricator closer to our customer base, both here and abroad. My favorite, of course, is Viant/Meraqi. The real question is what prompted her to say that when she did?

Buyout/Merger - The ultimate information suppressor. Nothing else even comes close. I have argued for awhile now that we are ripe for the pickin'. Legislation (No Pain Act) recently passed paving the way to widespread usage in the US. In the US alone this would require millions of units, at a minimum. Waiting for CMMS and/or insurance acceptance will end up being a very expensive, career-ending decision. International deals are in place. Interest is growing by the day. At any medical device company, we should be at the top of the list for acquisition. IMO, Viant/Meraqi is a possibility.

A buyout/merger would explain every second of silence. An NDA would be enforced w/ maximum penalty of, up to and including, end of negotiations. A deal of this magnitude would require massive legal-beagle arrangements, consultations, etc, both domestically and internationally. Maybe even 2 extra weeks courtesy of the Orange of Head? Whoever leaked would be terminated w/ immediate effect and would forever be a pariah.

Customer Base (actual & potential) - No explanation needed. Well, bashturds do, but then again their self-imposed stupidity and overall nastiness is the stuff of legends. Poor babies.

Distributors, Agreements & Contracts (DA&C) - OEMs do not exist. KT Tape, DonJoy, Adcock-Ingram, et. al., are illusions, at best. They do not order, stock, or sell product. Agreements & Contracts are for sissies.

note on Synergy - Management clearly stated they have a signed contract. If they lied about that it means prison time. That is an obvious case of fraud and misrepresentation. You may not like her, CEO Kelly, but accusing her of that is the stuff of libel and slander. Tread lightly.

NDAs - ssssssshhhhhhhhhhuuuussssssshhhhhhhhh !!!!!!! We were never here !!!

New Product Designs (NPD) - An elongated design is already on the table, possibly a renewable and/or a more powerful device. The science and research continues unabated whenever financially feasible. Or am I confusing the NPD w/ DA&C, which do not exist? Be thankful it is not an STD (Silly Token Design). What were you thinking?

"Sic parvis magma" - Greatness from small beginnings
Do yourself a favor ... BUY_MORE_SHARES

Real eyes realize real lies.

Later, WBeacham

BioElectronics Corporation (BIEL) Stock Research Links

BIEL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 35

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 51

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 119

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 291

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 595

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 321

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 0

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading

Top 5 Most Recently Viewed Articles

Market Reactions: Middle East Tensions and the Vance-Walz Debate

Updated Category News Views 71

Market Reactions to Middle East Tensions US stock futures are experiencing a downward trend as investors react to the escalating violence in the Middle East. With Iran claiming to have ceased its air bombardments on Israel, uncertainty still looms, as Israeli officials pledge a counterattack. This ongoing conflict has already impacted Wall Street, where equity values...

Continue Reading
Class Action Alert for Visa Inc. Shareholders Facing Losses

Updated Category News Views 91

Class Action Notification for Visa Inc. Shareholders The Gross Law Firm is reaching out to shareholders of Visa Inc. (NYSE: V) regarding an important class action that may affect them. If you purchased shares during a specific class period and have suffered losses, your participation could be significant in holding the company accountable. Understanding the Class Period...

Continue Reading
Coca-Cola's Earnings Report: Anticipated Insights and Analysis

Updated Category News Views 205

Coca-Cola's Earnings Report Overview The Coca-Cola Company (NYSE: KO) is on the cusp of unveiling its second-quarter financial results. Investors, analysts, and fans alike are closely watching what insights the beverage giant will provide during this crucial report. With notable figures in the U.S. market keeping an eye on Coca-Cola, the anticipation is palpable. Earnings...

Continue Reading
Maggiano's Unveils Gourmet Italian-American Classics Menu

Updated Category News Views 410

Introduction of Italian-American Classics at Maggiano's Maggiano's Little Italy is embracing the culinary heritage of Italian-American cuisine by introducing a new menu that reflects a dedication to high-quality ingredients and gourmet recipes. Under the expert guidance of award-winning Chef Anthony Amoroso, the restaurant's latest offerings promise to impress food...

Continue Reading
Recognizing Excellence: Pierce & O'Neill Founders Honored

Updated Category News Views 362

Pierce & O’Neill Founders Honored Among Top Attorneys Pierce & O’Neill, LLP, a renowned litigation boutique, is celebrating its founders, Jesse Pierce and Jack O’Neill, for their remarkable achievements in the legal field. Recently recognized in Lawdragon’s prestigious list of the 500 Leading Lawyers in America for 2025, this accolade showcases their exceptional...

Continue Reading